3C Patch® Medicare Claims Study

Terminated

• Conditions: Diabetic Foot Ulcer
• Interventions: Device: 3C Patch

• Registration Number: NCT03997526
• Lead Sponsor: Reapplix

Brief Summary

This prospective study will compare incidence rates of complete hard-to-heal diabetic foot ulcer healing in Medicare beneficiaries following application of the 3C Patch® plus usual care, tested against a historical control group of similar patients that received usual care during a randomized controlled trial.

Detailed Description

This is a prospective, observational, longitudinal, claims-based study with a historical control group. Data will be collected via claim forms and will be extracted directly from the Centers for Medicare \& Medicaid Services (CMS) Medicare Research Identifiable Files (RIFs), which contain all medical claims for 100% of Medicare beneficiaries enrolled in the Medicare fee-for-service program. The study will be conducted in accordance with relevant guidelines of a central institutional review board (IRB), relevant informed consent regulations, and all other applicable regulatory requirements.

Study Timeline

• Study First Submitted: 2019-06-21
• Study First Submitted QC: 2019-06-22
• Study First Posted: 2019-06-25
• Study Start: 2020-07-15
• Status Verified: 2022-02
• Primary Completion: 2022-02-21
• Study Completion: 2022-02-21
• Last Update Submitted: 2022-02-21
• Last Update Posted: 2022-03-09

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Medicare beneficiaries diagnosed with diabetic foot ulcer and receiving at least one treatment with the 3C Patch® System.
• Eligible ulcers will be hard-to-heal, meaning that the cross-sectional area will decrease by less than 50% during a four week period prior to the first application of the 3C Patch® (percentage change in cross-sectional area determined clinically by the treating physician by estimation at examination).
• Eligible ulcer's cross-sectional area will increase by less than 25% during a 4-week period prior to the first application of the 3C Patch® (percentage change determined clinically by treating physician by estimation at examination)
• The cross-sectional area of the index ulcer will be ≥50 and ≤1000 mm2 at the end of the 4 week period prior to the first application of the 3C Patch® (size determined clinically by the treating physician by estimation at examination).
• Participants will have the capacity to understand study procedures, and will be able to provide written informed consent.

Exclusion Criteria

• Presence of sickle-cell anemia, hemophilia, thrombocytopenia (<100x109/L) or other clinically significant blood dyscrasia
• Known potential infectivity of blood products, including known HIV and hepatitis
• Patient in dialysis
• Clinical signs of infection of the index ulcer or reason to suspect that infection is present
• Revascularization procedure in the affected limb planned, or undertaken within the 4 weeks prior to the first application of the 3C Patch®
• Current treatment with cytotoxic drugs or with systemically administered glucocorticoids or other immunosuppressants
• Treatment of foot ulcers with growth factors, stem cells or equivalent preparation within the 8 weeks prior to the first application of the 3C Patch®
• The need for continued use of negative pressure wound therapy
• Likely inability to comply with the need for follow up visits because of planned activity
• Participation in another interventional clinical foot ulcer-healing trial within the 4 weeks prior to the first application of the 3C Patch®
• Prior enrollment in this study
• Judgement by the investigator that the patient does not have the capacity to understand the study procedures or provide written informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
3C Patch treatment	3C Patch	Medicare beneficiaries with diabetes and hard-to-heal non-healing ulcers of the foot will receive usual care (i.e., care consistent with the IWGDF guidance on use of interventions to enhance the healing of chronic ulcers of the foot in diabetes) supplemented by the application of the 3C Patch (A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process)

Primary Outcome Measures

Name	Time	Method
Complete healing	within 20 weeks of the first application of the 3C Patch.	Rate (%) of complete healing of hard-to-heal diabetic foot ulcers in Medicare beneficiaries following application of the 3C Patch®.

Secondary Outcome Measures

Name	Time	Method
Major amputation - target limb	24 weeks	The incidence of major (above ankle) amputation affecting the target limb by 24 weeks
Minor amputation - contralateral limb	24 weeks	The incidence of minor amputation affecting the contralateral limb by 24 weeks
Number of 3C Patch® treatments administered	20 weeks	The number of 3C Patch® treatments administered within 20 weeks of initial application of the 3C Patch®.
Major amputation - contralateral limb	24 weeks	The incidence of major amputation affecting the contralateral limb by 24 weeks
Minor amputation - target limb	24 weeks	The incidence of minor (below ankle) amputation affecting the target limb by 24 weeks

Trial Locations

Locations (6)

Opelousas General Hospital Wound Center; 🇺🇸 Opelousas, Louisiana, United States

Mayo Clinic; 🇺🇸 Phoenix, Arizona, United States

Natchitoches Regional Medical Center; 🇺🇸 Natchitoches, Louisiana, United States

Southeast Wound Care and Hyperbaric Medical Center; 🇺🇸 Cape Girardeau, Missouri, United States

Regional One Physician Specialists; 🇺🇸 Poplar Bluff, Missouri, United States

UNC Chapel Hill; 🇺🇸 Chapel Hill, North Carolina, United States